Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I, Necchi A, Pircher A, Tsaur I, Marra G, Kasivisvanathan V, Kretschmer A, Mathieu R, Ceci F, van den Bergh RCN, Thibault C, Tilki D, Valerio M, Surcel C, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Heidegger I, et al. Among authors: kretschmer a. Eur Urol Oncol. 2021 Oct;4(5):745-754. doi: 10.1016/j.euo.2020.10.010. Epub 2020 Nov 23. Eur Urol Oncol. 2021. PMID: 33243663 Review.
[Imaging diagnostics of advanced prostate cancer].
Kretschmer A, Seitz M, Graser A, Stief CG, Tilki D. Kretschmer A, et al. Urologe A. 2013 Apr;52(4):497-503. doi: 10.1007/s00120-012-3095-z. Urologe A. 2013. PMID: 23483268 German.
68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP. Herlemann A, et al. Among authors: kretschmer a. Eur Urol. 2016 Oct;70(4):553-557. doi: 10.1016/j.eururo.2015.12.051. Epub 2016 Jan 19. Eur Urol. 2016. PMID: 26810345
Local treatment for metastatic prostate cancer: A systematic review.
Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. Tilki D, et al. Among authors: kretschmer a. Int J Urol. 2018 May;25(5):390-403. doi: 10.1111/iju.13535. Epub 2018 Mar 23. Int J Urol. 2018. PMID: 29572963
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP). Gandaglia G, et al. Among authors: kretschmer a. BJU Int. 2018 Nov;122(5):823-830. doi: 10.1111/bju.14391. Epub 2018 Jun 3. BJU Int. 2018. PMID: 29772103
Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?
Ploussard G, Borgmann H, Briganti A, de Visschere P, Fütterer JJ, Gandaglia G, Heidegger I, Kretschmer A, Mathieu R, Ost P, Sooriakumaran P, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R; EAU-YAU Prostate Cancer Working Group. Ploussard G, et al. Among authors: kretschmer a. World J Urol. 2019 Feb;37(2):243-251. doi: 10.1007/s00345-018-2399-z. Epub 2018 Jul 2. World J Urol. 2019. PMID: 29967944 Review.
284 results